Currently, adjuvant chemotherapy is not recommended for all patients with Stage II CRC in Japan; however, these results suggest that postoperative adjuvant chemotherapy should be considered for Stage II small-bowel cancer with SMAD4 mutations because of the high risk of recurrence. Here, SMAD4 is linked to colorectal carcinoma.